Stay updated on Telisotuzumab vs Docetaxel in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Telisotuzumab vs Docetaxel in NSCLC Clinical Trial page.

Latest updates to the Telisotuzumab vs Docetaxel in NSCLC Clinical Trial page
- Check4 days agoChange DetectedAn NIH announcement about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the site navigation, and the displayed revision changes from v3.7.1 to v3.7.2. The page still shows a 403 error instead of the study record.SummaryDifference1%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe footer’s ClinicalTrials.gov revision indicator changes from v3.7.0 to v3.7.1 while the page remains a 403 Forbidden error.SummaryDifference0.2%

- Check32 days agoChange DetectedDifference20%

- Check39 days agoChange DetectedThe page now lists additional study sites and a Find contact information entry, signaling an expanded network of locations and updated access to study contacts for the trial.SummaryDifference0.1%

- Check53 days agoChange DetectedThe page revision was updated to v3.6.6, replacing the previous v3.6.5, indicating an administrative update to the record. This does not reflect changes to the study details themselves.SummaryDifference0.0%

- Check60 days agoChange DetectedA line reading '2023 ( U.S. NIH Grant/Contract )' was added to the study's identifiers, indicating NIH funding for the trial. This adds funding attribution to the study record.SummaryDifference0.0%

Stay in the know with updates to Telisotuzumab vs Docetaxel in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Telisotuzumab vs Docetaxel in NSCLC Clinical Trial page.